Last reviewed · How we verify

Bupivacaine Injection

Ciusss de L'Est de l'Île de Montréal · FDA-approved active Small molecule

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Local anesthesia for infiltration, nerve block, epidural, and spinal anesthesia, Pain management in surgical and dental procedures.

At a glance

Generic nameBupivacaine Injection
Also known asevaluation of pain by using two different types of local anesthesia, Marcaine, Bupivacaine Hydrochloride Injection, stellate ganglion block, Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
SponsorCiusss de L'Est de l'Île de Montréal
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, stabilizing the neuronal membrane and raising the threshold for electrical excitability. This action prevents depolarization and propagation of action potentials, resulting in loss of sensation in the injected area. It has a longer duration of action compared to other local anesthetics due to its high lipophilicity and protein binding.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: